Adenovirus Clinical Trial
Official title:
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VSTs produced here at St. Jude in treating the participant's infection. Primary objective To determine the efficacy of VSTs to achieve a ≥1 log10 reduction in CMV and/or ADV viral load in the peripheral blood 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection, the objective is to achieve a reduction to below the threshold of detection. Secondary objectives - Determine the safety of VSTs when used to treat CMV and/or ADV viremia post-HCT. - Determine the proportion of patients who achieve a negative viral load at 3 months post-infusion. - Assess the persistence of response for 6 months post-infusion.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | December 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: - Patients who have undergone haploidentical HCT or a matched-sibling/matched-unrelated donor HCT, and have CMV and/or ADV detected by PCR in the peripheral blood refractory to antiviral therapy per institutional BMTCT SOP 20.05. - Definition of "refractory" viremia is persistent positive CMV or ADV viremia after 14 days of treatment per institutional SOP, or an increasing copy number (=1 log) after 7 days of treatment. - Patients have no suspected or confirmed GVHD. - Availability of haploidentical donor for isolation of virus-specific T-cells. - Have not received a Donor Lymphocyte Infusion in the past 4 weeks. - Female patients of childbearing age must have a negative pregnancy test. - Subject, parent, or guardian are capable of giving signed informed consent. - Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%. - Patients must have a bilirubin less than or equal to 2.5mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal. - Patients must have an estimated glomerular filtration rate (GFR) greater than 60mL/min/1.73m2. - Patients must be free of severe infection which upon determination of the principal investigator precludes therapy with VST. - Patients must have FVC >50% predicted or if unable to perform pulmonary function testing must maintain pulse oximetry saturation > 92% on room air. - Patients must have engrafted with an ANC >500 cells/mm3 for 3 consecutive days. Inclusion criteria for donors - Age =18 years. - At least single haplotype matched (=3/6) family member. - Donor will be identical to the stem cell donor (Cohort A) or different from the stem cell donor (Cohort B). - HIV negative. - For females of childbearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND not lactating with intent to breastfeed. - Regarding donation eligibility, is identified as either having completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance or does not meet 21CFR 1271 eligibility requirements but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21CFR. - Identified recipient with CMV and/or ADV reactivation post-HCT. Exclusion Criteria: - Active GVHD. - Pregnancy. - Inability to provide consent. - Need for vasopressor or ventilatory support Patients receiving steroids >0.5 mg/kg prednisone equivalent at the time of VST infusion - Donor Lymphocyte Infusion within 4 weeks prior to VST infusion. - Receipt of Thymoglobulin or Alemtuzumab within 30 days of VST infusion. |
Country | Name | City | State |
---|---|---|---|
United States | St . Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Degree of reduction of CMV and/or ADV viral load | The primary objective of this clinical study is to evaluate the efficacy of adoptively transferred CMV- and ADV-specific haploidentical T-cells in patients who have undergone allogeneic HCT. This primary endpoint is defined as =1 log10 reduction in CMV and/or ADV viral load 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection the endpoint will be a reduction to below the threshold of detection. The success rate will be evaluated using descriptive statistics (sample proportion and standard error). Patients with both CMV and ADC detected will count as success if reduction occurs in one or both of CMV and ADV. | 4 weeks after VST infusion | |
Secondary | Incidence of infusion-related grade 3-5 adverse events 24 hours after infusion | The incidence of infusion-related grade 3-5 adverse events will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 24 hours after infusion | |
Secondary | Incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy | The incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 4 weeks after VST infusion | |
Secondary | Incidence of Grade 3-4 Neurotoxicity of any duration | The incidence of Grade 3-4 Neurotoxicity of any duration will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 4 weeks after VST infusion | |
Secondary | Incidence of Grade 3-4 GVHD | The incidence of Grade 3-4 GVHD will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 4 weeks after VST infusion | |
Secondary | Incidence of grade 3-5 non hematologic toxicities attributable to VST | The incidence of grade 3-5 non hematologic toxicities attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 4 weeks after VST infusion | |
Secondary | Incidence of secondary graft failure attributable to VST | The incidence of secondary graft failure attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) | 4 weeks after VST infusion | |
Secondary | Proportion of patients who achieve a negative viral load result at 3 months | The proportion of patients who achieve a negative viral load result at 3 months will be assessed using descriptive statistics (sample proportions with standard errors) | 3 months after VST infusion | |
Secondary | Persistence of response at 6 months post-infusion | The persistence of response at 6 months post-infusion will be assessed using descriptive statistics (sample proportions with standard errors) | 6 months after VST infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01195571 -
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
|
Phase 1 | |
Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
Active, not recruiting |
NCT05575492 -
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
|
Phase 1/Phase 2 | |
Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
Completed |
NCT00456664 -
CMV Disease and IRIS in HIV-1 Infected Persons
|
N/A | |
Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
Completed |
NCT01160081 -
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
|
N/A | |
Completed |
NCT00467532 -
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
|
N/A | |
Terminated |
NCT03127787 -
Clinical Performance Evaluation of DxN CMV Assay
|
||
Completed |
NCT00366717 -
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
|
N/A | |
Completed |
NCT00815802 -
Detection of Human Cytomegalovirus in the Saliva
|
N/A | |
Completed |
NCT01646645 -
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Suspended |
NCT00668798 -
Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms
|
N/A | |
Completed |
NCT00214240 -
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
|
N/A | |
Completed |
NCT00330018 -
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
|
Phase 3 | |
Completed |
NCT01895049 -
Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
|
Phase 4 | |
Completed |
NCT02083042 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01162330 -
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
|
N/A |